Related Experiment Video
Updated: Jan 29, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape
Lawrence Zeldin1, Yevgeniy Brailovsky1, Mathew S Maurer1
1Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA;
None:
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as a significant yet underdiagnosed cause of heart failure. Advancements in the noninvasive imaging that facilitates diagnosis at an earlier stage of disease and treatment have marked a paradigm shift in the management of this previously fatal disease. This review outlines the epidemiology, pathophysiology, diagnosis, and treatment of ATTR-CM, with an emphasis on the recent developments transforming the field, including an ability to diagnose most patients without a biopsy, the shift toward screening or active ascertainment, the development of several new therapies, and a better understanding of how to employ standard heart failure therapies in patients with this disease. Additionally, the review explores questions that have emerged from these developments.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

